



PATENT/Docket No.: 6207.N CN1  
Serial No.: 09/532,396  
Page No. 1

CP 1615 #5  
1/19/01

**CERTIFICATE OF MAILING (37 CFR 1.8)**

Date of Deposit with U.S. Postal Service: January 8, 2001

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail under 37 CFR 1.8 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington D.C. 20231.

Julie K. Lyons, Legal Assistant

Name of Person Mailing Paper

Julie K Lyons  
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1615  
Examiner :  
Applicant(s) : Youmin Wang and W. Morowich  
Serial No. : 09/532,396  
Filed : March 22, 2000  
For : Pharmaceutical Emulsions for Retroviral Protease Inhibitors

Commissioner of Patents and Trademarks  
Washington, DC 20231

RECEIVED  
JAN 18 2001  
TECH CENTER 1600/2900

**SUPPLEMENTAL**  
**INFORMATION DISCLOSURE STATEMENT TRANSMITTAL**  
**UNDER 37 CFR 1.97 AND 1.98**

Sir:

**Information Disclosed.** The information disclosed consists of the following:

- ☐ **Form PL-1449.** Provided herewith are copies of patent(s) and/or publication(s) as listed in the attached form PL-1449.
- ☐ At least to the extent required under §1.98(a)(3), a concise explanation of the relevance of references listed in form PL-1449 is:
- ☐ contained in the above-captioned specification as filed;
  - ☐ provided in a communication enclosed with this paper;
  - ☐ provided in the International Search Report enclosed with this paper; and/or
  - ☐ not necessary as all of the references cited are in the English language.

- ☐ **Disclosure from Predecessor Application.** Provided herewith is a copy (or the copy is already present in the present file wrapper in accordance with §1.53(d)) of one or more forms PL-1449 and/or search/examination reports of record in this or a predecessor application, Serial No. filed, the benefit of which is claimed under 35 USC 120. Copies of references are present in the prosecution history of the referenced application and are not supplied herewith pursuant to §1.98(d).


**Basis for Consideration.** This information disclosure statement is entitled to consideration by the Office under:

- ☒ **§1.97(b)**, as being filed within three months of the filing date of the above-captioned application and/or the date of entry of the National Stage, if later, and/or before the mailing date of the first Office action on the merits. Applicant(s) is/are unaware that any office action has issued in this case. However, in the event a first office action has issued, prior to the mailing of this document, then authorization is given to charge the late fee to the deposit account identified below.
- ☐ **§1.97(c)**, as being filed after the period specified in §1.97(b), but before the mailing date of a final action under §1.113 and/or the notice of allowance under §1.311. Consideration of this information disclosure statement at this time is requested for the reason checked below:
- ☐ **Authorization is hereby provided to charge Deposit Account No. 21-0718 the fee set forth in §1.17(p), \$240.00**, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
- ☐ A statement as specified in 37 CFR 1.97(e) below.
- ☐ **§1.97(d)**, as being filed after the period specified in §1.97(c), but on or before payment of the issue fee and is accompanied by:
- ☐ **Authorization to charge Deposit Account No. 21-0718 the fee set forth in §1.17(i), \$130.00**, or such greater or lesser amount as the Commissioner may from time to time prescribe by rule. Triplicate copies of this paper are provided to facilitate the charge to the Deposit Account.
- ☐ A petition requesting consideration of the information disclosure statement; and
- ☐ A statement as specified in 37 CFR 1.97 (e) below.
- ☒ **§1.97(e)**, this is a **supplemental information disclosure statement**. A prior information disclosure statement has already been filed. Applicant certifies, as provided in 37 CFR 1.97 (e), that

- ☐ Each new item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.
- ☒ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing below, after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three (3) months prior to the filing of this statement.

**Disclaimer.** In accordance with §1.97(g) and (h), the filing of this information disclosure statement is not to be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56, and is not to be construed as a representation that a search has been made.

Respectfully submitted,

  
\_\_\_\_\_  
Lucy X. Yang, Attorney  
Registration No. 40,259

Date: 1-4-2001

Pharmacia & Upjohn Company  
Global Intellectual Property  
301 Henrietta Street  
Kalamazoo, Michigan 49001

Telephone No. (616) 833-9536 or (616) 833-9500  
Telefax No. (616) 833-8897 or (616) 833-2316

Attachment(s)

- ☐ Form 1449 with copies of reference(s)  
☐ Form 1449 from predecessor application (no references)  
☐ Communication providing concise explanation of relevance  
☒ International Search Report  
☒ ASSOCIATE POWER OF ATTORNEY (Engelmann/Zhang)